Friday, March 28, 2025

ATS Life Sciences and Staubli Robotics Collaborate to Develop a Multi-Million-Dollar End-to-End Syringe Manufacturing System

Related stories

Siemens acquires Altair to expand AI-powered industrial software

Siemens has completed the acquisition of Altair Engineering Inc.,...

GMI Cloud Unveils Affordable High-Performance AI Engine

GMI Cloud, a leading AI-native GPU cloud provider, announced...

GetReal Security Raises $17.5M to Combat AI Threats

New capital will support ongoing product innovation for the...

Polyhedra Unveils Breakthrough in AI Trust Infrastructure

Polyhedra announced the release of zkPyTorch, a groundbreaking compiler...

Imandra Launches CodeLogician: AI for Math Code Reasoning

Imandra Inc., a pioneer in neurosymbolic AI and automated...
spot_imgspot_img

The ATS Life Sciences Systems engineering team, leveraging the power of Staubli Robotics capabilities, has been selected to build a large-scale syringe assembly system in the eastern United States. The system will span from the molding systems to the end-of-line pack-out, resulting in a highly efficient and reliable system consistently delivering quality and performance.

The collaboration between ATS Life Sciences Systems (LSS) and Staubli Robotics combines the expertise of two industry leaders to deliver innovative solutions tailored to meet the unique needs of customers, in this case a 300 parts-per-minute, end-to-end syringe assembly system. The system is built on ATS LSS’ high-performance assembly platform and incorporates Staubli Robotics’ advanced technology, featuring eight Staubli robots employed in various operations, including mold unloading, siliconization, tip capping, and robust quality and visual inspections.

Also Read: Snow Software Unveils Snow Copilot, its First Generative AI Assistant, Built to Solve Large Challenges in IT Asset Management and FinOps

Olivier Cremoux leads the North American Sales and Marketing team for Staubli Pharma and Med Devices, based in Duncan, South Carolina. He states, “Staubli and ATS LSS have established a strategic partnership to develop high-end automation projects for the pharma and medical industry. While our companies have collaborated for years, creating state-of-the-art automated solutions for device manufacturing and drug compounding, we are reaching a new milestone with this great success.”

Andy Glaser, VP of Global Sales at ATS Life Sciences Systems, comments, “By harnessing the expertise of industry leaders like Staubli and pairing them with the innovative solutions that ATS LSS has become known for, we address our unique customer challenges and continue to drive innovative solutions which fundamentally tackles the market demand for medical devices.”

SOURCE: PRWeb

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img